Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Jianguo Wen, Ph.D.

Jianguo Wen, Ph.D.


Assistant Member
Houston Methodist Research Institute 

E-mail: jwen@houstonmethodist.org
Phone: 713-441-3593


M.S.   Northwest Sci-Tec University of Agriculture and Forestry, Shaanxi, China

Fudan University, Shanghai, China (Genetics)

Postdoctoral Training

Postdoctoral Fellowship, The Methodist Hospital Research Institute, Houston, TX


Dr. Jianguo Wen earned his Ph.D. in Genetics from Fudan University in 2004. He joined Houston Methodist Research Institute in 2005 and completed his postdoctoral training in the Department of Pathology.

Description of Research

Dr. Wen’s research program focuses on pathogenesis and preclinical treatment of multiple myeloma. Current research efforts aim to develop therapies targeting multiple myeloma cancer stem cells.

Major Areas of Research

Cancer, stem cells, multiple myeloma

Recent Publications

Podberezin M, Wen J, Chang CC. Cancer Stem Cells: A Review of Potential Clinical Applications. Arch Pathol Lab Med. 2012 Nov 15. PMID:23153183

Fan J, Deng X, Gallagher JW, Huang H, Huang Y, Wen J, Ferrari M, Shen H, Hu Y. Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Transact A Math Phys Eng Sci. 2012 May 28;370(1967):2433-47.

McGowan P, Nelles N, Wimmer J, Williams D, Wen J, Li M, Ewton A, Curry C, Zu Y, Sheehan A, Chang CC. Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system. Am J Clin Pathol. 2012 Apr;137(4):665-70.

Peng H, Wen J, Zhang L, Li H, Chang CC, Zu Y, Zhou X. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes. Mol Biosyst. 2012 Apr;8(4):1366-74.

Wen J, Feng Y, Bjorklund CC, Wang M, Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, Chang CC. Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol Cancer Ther. 2011 Jan;10(1):148-58.

Xia Z, Wen J, Chang CC, Zhou X. NSMAP: a method for spliced isoforms identification and quantification from RNA-Seq. BMC Bioinformatics. 2011 May 16;12:162.

Lukianova-Hleb EY, Samaniego AP, Wen J, Metelitsa LS, Chang CC, Lapotko DO. Selective gene transfection of individual cells in vitro with plasmonic nanobubbles. J Control Release. 2011 Jun 10;152(2):286-93.

Peng H, Wen J, Li H, Chang J, Zhou X. Drug inhibition profile prediction for NF?B pathway in multiple myeloma. PLoS One. 2011 Mar 7;6(3):e14750.

Beck D, Ayers S, Wen J, Brandl MB, Pham TD, Webb P, Chang CC, Zhou X. Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. BMC Med Genomics. 2011 Feb 23;4:19.

Feng Y, Wen J, Mike P, Choi DS, Eshoa C, Shi Z, Zu Y, Chang CC. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev. 2010 Sep;19(9):1289-96.

Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L, Pretie A. Hector, Kamble T. R, Zu Y, Ballon J. D and Chang C. C. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res. 2010; 34(1):85-92.

Feng Y, Ofek G, Choi DS, Wen J, Hu J, Zhao H, Zu Y, Athanasiou KA, Chang CC. Unique biomechanical interactions between myeloma cells and bone marrow stroma cells. Prog Biophys Mol Biol. 2010; 103(1):148-156.

Feng Y, Wen J, Chang CC. p38 Mitogen-activated protein kinase and hematologic malignancies. Arch Pathol Lab Med. 2009 Nov; 133(11):1850-6.

Huang W, Yang X, Zhou X, Monzon FA, Wen J, Hagenkord JM, Wu L, Keever-Taylor C, Novoa-Takara L, Wong STC, Young K, Chang C. Multiple distinct clones may co-exist in different lineages in myelodysplastic syndromes. Leuk Res. 2009; 33:847-53.

Conway E. J, Wen J, Feng Y, Mo A, Huang W. T, Keever-Taylor A. C, Hari P, Vesole H. D, Chang C. C. Phenotyping Studies of Clonotypic B Lymphocytes From Patients With Multiple Myeloma by Flow Cytometry. Arch Pathol Lab Med. 2009; 133:1594-1599.

Wen J, Cheng H, Rice L, Liu S, Mo A, Huang J, Zu Y, Ballon DJ, Chang C. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haemotol. 2008; 140:169-80.